| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 11/24/2005 | WO2005110114A1 Liquid nutritional supplement and method for preparing same |
| 11/24/2005 | WO2005110085A2 Use of selective cytokine inhibitory drugs in myelodysplastic syndromes |
| 11/24/2005 | WO2005110013A2 Methods, compositions, and preparations for delivery of immune response modifiers |
| 11/24/2005 | WO2005110002A2 Anti-inflammatory and anticeptic suppository exhibiting a regeneration effect |
| 11/24/2005 | WO2005094800A3 A co-precipitated cefepime composition and process for preparation thereof |
| 11/24/2005 | WO2005090299A3 Carbamates as hiv anti-viral agents |
| 11/24/2005 | WO2005090296A3 N-substituted benzene sulfonamides |
| 11/24/2005 | WO2005089502A3 Methods for the treatment of synucleinopathies |
| 11/24/2005 | WO2005089066A3 Pharmaceutical compositions, methods of formulation thereof and methods of use thereof |
| 11/24/2005 | WO2005087722A9 Diphenylmethyl compounds useful as muscarinic receptor antagonists |
| 11/24/2005 | WO2005087253A3 Interferon-beta for anti-virus therapy for respiratory diseases |
| 11/24/2005 | WO2005086904A3 Therapeutic modulation of ppar (gamma) activity |
| 11/24/2005 | WO2005086768A3 Enhanced production of functional proteins from defective genes |
| 11/24/2005 | WO2005086638A3 Analogs exhibiting inhibition of cell proliferation, methods of making, and uses thereof |
| 11/24/2005 | WO2005084685A3 Boronate medicaments suitable for short duration anticoagulation |
| 11/24/2005 | WO2005084222A3 Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| 11/24/2005 | WO2005082925A3 Novel steroid agonist for fxr |
| 11/24/2005 | WO2005082856A3 Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors |
| 11/24/2005 | WO2005079317A3 Prostate hypertrophy treatment composition and method |
| 11/24/2005 | WO2005079267A3 Methods for protein production |
| 11/24/2005 | WO2005079192A3 Novel treatment |
| 11/24/2005 | WO2005077373A3 Treatment of gastro-esophageal reflux disease (gerd) |
| 11/24/2005 | WO2005077368A3 Treatment of gastro-esophageal reflux disease (gerd) |
| 11/24/2005 | WO2005077343A9 Novel drugs and diagnostic compositions for use in the treatment and diagnosis of neurodegenerative diseases or amyloid diseases |
| 11/24/2005 | WO2005076829A3 Stable loratadine spill resistant formulation |
| 11/24/2005 | WO2005072706A3 Nanosuspensions of anti-retroviral agents for increased central nervous system delivery |
| 11/24/2005 | WO2005065665A3 Highly concentrated pourable aqueous solutions of potassium ibuprofen, their preparation and their uses |
| 11/24/2005 | WO2005062898A3 Enhanced absorption of modified release dosage forms |
| 11/24/2005 | WO2005060951A3 Anti-neoplastic agents, combination therapies and related methods |
| 11/24/2005 | WO2005058752A3 Higher fullerenes useful as radical scavengers |
| 11/24/2005 | WO2005058295A3 Use of sphingosine-1-phosphate (s1p) receptor agonists for the treatment of brain degenerative diseases |
| 11/24/2005 | WO2005051978A3 Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof |
| 11/24/2005 | WO2005046641A3 Compositions and methods for treating a posterior segment of an eye |
| 11/24/2005 | WO2005046604A3 Heteroaryl-hydrazone compounds |
| 11/24/2005 | WO2005041875A3 Dopamine-, norepinephrine- and serotonin- transporter- selective heterocyclic compounds and their therapeutic applications |
| 11/24/2005 | WO2005039637A3 Combinations of an aldosterone receptor antagonist, a diuretic and an angiotensin blocker |
| 11/24/2005 | WO2005039498A3 Methods of treating cancer with hdac inhibitors |
| 11/24/2005 | WO2005037230A3 Compositions and methods for treating heart failure |
| 11/24/2005 | WO2005034871A3 Methods for treating diseases and conditions with inverse agonists |
| 11/24/2005 | WO2005032489A3 Coated metal pyrithione particles for treatment of microorganisms |
| 11/24/2005 | WO2005028539A3 Multi-arm polymer prodrugs |
| 11/24/2005 | WO2005026112A3 Methods of treating a disorder |
| 11/24/2005 | WO2005025535A8 Methods for preparing pharmaceutical compositions |
| 11/24/2005 | WO2005016249A3 Compositions of a chromene or phenyl acetic acid cyclooxygenase-2 selective inhibitor and an ace inhibitor for the treatment of central nervous system damage |
| 11/24/2005 | WO2005011647A2 Pharmaceutical composition |
| 11/24/2005 | WO2005000246A3 Methods and compositions for treating rheumatoid arthritis |
| 11/24/2005 | WO2005000205A3 Methods and compositions for modulating serum cortisol levels |
| 11/24/2005 | WO2004110420A8 Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen |
| 11/24/2005 | WO2004104217A3 Protein kinase c zeta as a drug target for arthritis and other inflammatory diseases |
| 11/24/2005 | WO2004103271A3 Disease prevention and vaccination prior to thymic reactivations |
| 11/24/2005 | WO2004091630A8 Remedies for diseases to be applied to eye |
| 11/24/2005 | WO2004091502A8 1,2,4-oxadiazole benzoic acid compounds |
| 11/24/2005 | WO2004089313A3 Novel olanzapine forms and related methods of treatment |
| 11/24/2005 | WO2004060303A3 Methods and reagents for the enhancement of virus transduction in the bladder epithelium |
| 11/24/2005 | WO2004009227A3 Biodegradable polyurethane/urea compositions |
| 11/24/2005 | US20050261756 Coated stent |
| 11/24/2005 | US20050261750 Method and apparatus for acne treatment |
| 11/24/2005 | US20050261584 Devices and methodologies useful in body aesthetics |
| 11/24/2005 | US20050261508 Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE), pharmaceutical methods and compositions employing such inhibitors, and processes for evaluating the NHE-inhibitory efficacy of compounds |
| 11/24/2005 | US20050261502 2-Amino-4-(1,3-benzodioxol-5-yl)-6-benzyloxy-3,5-pyridinedicarbonitrile, acting as adenosine-receptor-selective ligands, for the prophylaxis and/or treatment of cardiovascular disorders |
| 11/24/2005 | US20050261501 e.g. 1-({[9-(hydroxymethyl)-3-oxaspiro[5.5]undec-9-yl]amino}acetyl)-2-pyrrolidinecarbonitrile; dipeptidyl-peptidase IV inhibitor; antidiabetic, hypoglycemic agent; non-insulin dependent diabetes, obesity |
| 11/24/2005 | US20050261496 3-(Morpholin-4-ylsulfonyl)-5-(1,3-thiazol-2-yl)-1H-indole-2-carboxamide; inhibiting, modulating and/or regulating signal transduction of both receptor and non-receptor tyrosine kinases; anticarcinogenic, -diabetic, -arhtritic, -inflammatory agents; psoriasis; angiogenesisinhibitors; liver cirrhosis |
| 11/24/2005 | US20050261495 Lactam Compound |
| 11/24/2005 | US20050261418 Crosslinked polymers containing biomass derived materials |
| 11/24/2005 | US20050261379 Spray Oil and Method of Use Therefor for Controlling Turfgrass Pests |
| 11/24/2005 | US20050261378 Process for decreasing adiposity using vitamin A as a dietary supplement |
| 11/24/2005 | US20050261377 Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction |
| 11/24/2005 | US20050261376 reduction of 4,5-dimethoxy-1-cyano-benzocyclobutane, resolution with optically active diacid (N-acetyl-L-glutamic acid), amidification and reduction; improved yield and optical purity; chemical intermediates; antiischemic agents |
| 11/24/2005 | US20050261375 Method for providing a cathartic effect |
| 11/24/2005 | US20050261373 Prostaglandin compounds for the treatment of obesity |
| 11/24/2005 | US20050261372 NMDA receptor agonist; neurodegenerative diseases, cognition activator; autism, schizophrenia, Alzheimer's disease; glycinergic and/or glutaminergic transmission activator |
| 11/24/2005 | US20050261371 Administering valproic acid or salts to treat Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, stroke, and other nervous system disorders |
| 11/24/2005 | US20050261369 Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor |
| 11/24/2005 | US20050261368 N-(tert-butyl)-2-methoxy-2-(4-hydroxy-3-(hydroxymethyl)phen-1-yl)-ethanamine; reduced steps for synthesis while maximizing synthetic yield without sacrificing compound purity; adding D-dibenzoyltartaric acid to mixture of racemic salbutamol in methanol; crystallizing, recrystalling in second solvent |
| 11/24/2005 | US20050261367 Methods for treating dermatological and other health-related conditions in a patient |
| 11/24/2005 | US20050261366 Tri(alkylcarboxylato)gallium (III) products and pharmaceutical compositions containing them |
| 11/24/2005 | US20050261365 Transthyretin stabilization |
| 11/24/2005 | US20050261364 Stereoisomeric form and a second antiretroviral compound; treating multidrug resistant HIV infections; protein plasma binding of the protease inhibitor has minimal or no effect on its potency; effective over a broad range of HIV mutants, bioavailability |
| 11/24/2005 | US20050261363 Acetone extraction for gamboge resins for tumor purification for antitumor and anticancer agent cells with acetone extraction |
| 11/24/2005 | US20050261362 Method of increasing endogenous adiponectin and leptin production |
| 11/24/2005 | US20050261361 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| 11/24/2005 | US20050261360 Dissolving the crystalline form in acetone, allowing to convert to amorphous form and then precipitating it out |
| 11/24/2005 | US20050261359 Novel processes for preparing amorphous atorvastatin hemi-calcium |
| 11/24/2005 | US20050261356 Methods and compositions for the treatment of chronic lymphocytic leukemia |
| 11/24/2005 | US20050261355 Carvedilol hydobromide |
| 11/24/2005 | US20050261354 [2-Alkyl-3-(phenylaminocarbonyl)-4-(4-pyrimidinyl, 5-pyrrolyl, or 4-pyridinyl)-5-(p-fluorophenyl)pyrrol-1-yl]dihydroxyalkanoic acids and 6-alkyl-gamma-hydroxyvalerolactones; antiinflammatory agents; carciovascular disorders; P38 map kinase inhibitors |
| 11/24/2005 | US20050261353 Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents |
| 11/24/2005 | US20050261352 Such as methyl 2-bromo-5-formyl-3-(3-methyl-2-buten-1-yl)-3H-imidazole-4-carboxylate |
| 11/24/2005 | US20050261351 Process for preparing ondansetron hydrochloride dihydrate having a defined particle size |
| 11/24/2005 | US20050261349 Medicine for prevention or treatment of diabetes |
| 11/24/2005 | US20050261348 (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent |
| 11/24/2005 | US20050261346 N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide;modified amidine elements of high potency in vitro, excellent pharmacological and pharmaceutical properties in vivo |
| 11/24/2005 | US20050261345 beta-amyloid antiaggregating properties; 2,5-Bis-{6-[ethyl-(2-methoxy-benzyl)-amino]-hexylamino}-[1,4]benzoquinone for example |
| 11/24/2005 | US20050261344 Treatment of lower urinary tract symptoms associated with overactive bladder in men and women |
| 11/24/2005 | US20050261343 Anthranilamides and their use as pharmaceutical agents |
| 11/24/2005 | US20050261342 Metabolites of (+)-(2S,3S)-3(2-methoxy-5- trifluoromethoxybenzylamino)-2-phenyl-piperidine |
| 11/24/2005 | US20050261341 reacting (R)-alpha-(2,3-dimethoxyphenyl)-4-piperidinemethanol with 4-fluorophenylethyl alkylating agent |
| 11/24/2005 | US20050261340 Selective serotonin receptor inverse agonists as therapeutics for disease |
| 11/24/2005 | US20050261339 Jun N-terminal kinase inhibitors; neurodegenerative diseases; Alzheimer's disease; amyotrophic lateral sclerosis; multiple sclerosis; spinocerebellar ataxia |
| 11/24/2005 | US20050261338 Beta2-adrenergic receptor agonists |